As both FOXO3 and FOXO1 inhibited leukaemia growth in our assays, we treated 697 and REH cells with Selinexor to increase pan-FOXO activity [49, 50, 55], achieving IC50 in the 50–100 nanomolar range. Here, FOXO1 is linked to leukemia.